|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current Assets: | |||||||||||||||
| Cash | |||||||||||||||
| Trade accounts receivable, net of allowance of $0 and $2,598 at June 30, 2018 and December 31, 2017, respectively | |||||||||||||||
| Medical supplies | |||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||
| Total current assets | |||||||||||||||
| Property and equipment, net | |||||||||||||||
| Intangible assets, net | |||||||||||||||
| Goodwill | |||||||||||||||
| Notes receivable | |||||||||||||||
| Investments in associates | |||||||||||||||
| Deferred tax asset | |||||||||||||||
| Other long-term assets | |||||||||||||||
| Total Assets | |||||||||||||||
| Liabilities and Shareholders' Equity | |||||||||||||||
| Current Liabilities: | |||||||||||||||
| Trade accounts payable | |||||||||||||||
| Accrued liabilities | |||||||||||||||
| Lines of credit | |||||||||||||||
| Subordinated notes payable | |||||||||||||||
| Current portion of capital leases | |||||||||||||||
| Current portion of long-term debt | |||||||||||||||
| Current portion of convertible promissory notes | |||||||||||||||
| Current portion of warrant and stock option derivative liabilities | |||||||||||||||
| Other current liabilities | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Lines of credit | |||||||||||||||
| Long-term capital leases, net of current portion | |||||||||||||||
| Long-term debt, net of current portion | |||||||||||||||
| Convertible promissory notes, net of current portion | |||||||||||||||
| Warrant and stock option derivative liabilities | |||||||||||||||
| Other long-term liabilities | |||||||||||||||
| Total liabilities | |||||||||||||||
| Contingently redeemable noncontrolling interest | |||||||||||||||
| Shareholders' Equity: | |||||||||||||||
| Common shares, no par value, unlimited shares authorized, 78,250,469 and 78,183,802 shares issued and outstanding at June 30, 2018 and December 31, 2017 | |||||||||||||||
| Additional paid in capital | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||
| Total shareholders’ equity attributable to Nobilis Health Corp. | |||||||||||||||
| Noncontrolling interests | |||||||||||||||
| Total shareholders' equity | |||||||||||||||
| Total Liabilities and Shareholders' Equity |
Loading...
